Rafarma’s global pharmaceutical strategy at a glance

Nicosia, Cyprus, May 18, 2021 (GLOBE NEWSWIRE) – Rafarma Pharmaceuticals, Inc. OTC: (RAFA) is an international biotechnology and pharmaceutical company that combines research centers and modern pharmaceutical production that meets international GMP standards.

Rafarma Pharmaceuticals has consolidated and is in the process of consolidating a number of industrial companies, the oldest of which dates back to 1931. The gross sales of finished products in 2020 both for the company itself and for the affiliates at the end year amounted to about US $ 75 million, profit was about US $ 15 million.

Since the establishment of the portfolio of companies, Rafarma has created a reliable business model focused on the development of high quality innovative medicines. These innovations, based on both internal research and external partnerships, ensure the continued growth of the company and its sustainable operation in the pharmaceutical market.

By developing new drugs in the short term, the company is strategically focusing on:

• development and marketing of radiopharmaceuticals and devices for nuclear medicine
• development of drugs for antibacterial and antiviral therapy using nanomaterials and nanotechnologies
• development and commercialization of innovative sterile biological, immunological and targeted drugs for the treatment of cancer
• development and marketing of medical equipment and medical products
• promotion of several other biotechnology projects

Rafarma implements industrial projects in Russia, Slovenia, Uzbekistan and also carries out marketing and trade activities active in China and in the countries of the Eurasian Economic Union. We are discussing our new industrial and scientific projects in USA, Czech Republic, Greece, Uzbekistan, Iraq, Malaysia, Indonesia, Korea, Argentina.

Drugs under development at Rafarma have a strong chance of becoming industry winners, enabling our company to build one of the most profitable and promising innovative drug portfolios of any biopharmaceutical company in Europe. from East, Central Asia and China.

Forward-looking statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained in this press release, statements made in this press release are forward-looking statements. . Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend” , “Could”, “would”, “estimate” or “continue”, or other negative variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by forward-looking statements. In addition, forward-looking statements represent the beliefs and assumptions of our management only as of the date hereof. Additional information regarding factors that may cause actual results to differ materially from these forward-looking statements can be found in the documents filed by the Company with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons why actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available. become available in the future.

For more information contact:
(307) 429-2029

Source link

About Catherine Sherrill

Check Also

Individual investors represent 42% of the ownership of CSPC Pharmaceutical Group Limited (HKG: 1093), while institutions represent 28%

A look at the shareholders of CSPC Pharmaceutical Group Limited (HKG: 1093) can tell us …

Leave a Reply

Your email address will not be published. Required fields are marked *